Clinical Trials Logo

Blood Platelet Disorders clinical trials

View clinical trials related to Blood Platelet Disorders.

Filter by:

NCT ID: NCT02135575 Completed - Clinical trials for Cardiovascular Diseases

Effects of Exercise Training on Cardiovascular Health in Middle-aged Women

Start date: May 2014
Phase: N/A
Study type: Interventional

The hypothesis of the present study is that physical training can oppose detrimental changes in cardiovascular and metabolic health associated with estrogen loss after menopause.

NCT ID: NCT02096523 Completed - Clinical trials for Inherited Platelet Disorders

Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder

Start date: November 2016
Phase: N/A
Study type: Interventional

The goal of this study is to identify the platelet defect responsible for the bleeding in families from our inherited platelet disorders Israeli-Palestinian registry. The investigators plan to characterize platelet proteome expression after removing high abundance proteins. The investigators will compare the proteome of sick and healthy members of families with inherited platelet disorders, and identify and validate structural proteins, signaling cascades and biomarkers for detection and diagnosis of unknown platelet disorders. The investigators expect to discover new key findings that allow better understanding of human platelet function and allow better diagnosis and treatment of patients with inherited platelet function disorders.

NCT ID: NCT01935245 Completed - Thrombocytopathy Clinical Trials

Platelet Function in Minimal Extracorporeal Circulation in CABG

ECCTEG
Start date: April 2013
Phase: N/A
Study type: Interventional

Rationale: Cardiac surgery with extracorporeal circulation (ECC) triggers platelets. Minimal extracorporeal circulation system (minimal-ECC) has several advantages compared with conventional ECC amongst less platelet activation. Platelet function can be analysed with thromboelastography (TEG) and multiple electrode aggregometry (MEA). Objective: The use of minimal ECC leads to less platelet dysfunction compared with conventional ECC in coronary artery bypass grafting (CABG) analysed with TEG and MEA Study design: Single center, prospective, randomized, pilot study Study population: Group 1: 20 patients undergoing CABG using minimal ECC. Patients continued the use of acetylsalicylic acid and discontinued the use of clopidogrel minimal 5 days preoperative. Group 2: 20 patients undergoing CABG using conventional ECC. Patients continued the use of acetylsalicylic acid and discontinued the use of clopidogrel minimal 5 days preoperative. Intervention: Group 1: CABG using minimal ECC Group 2: CABG using conventional ECC Main study parameters/endpoints: 1. Results of TEG and MEA, see detailed description 2. Per operative blood loss and total blood loss 24 hours after CABG 3. Total amount of transfused platelet units during CABG and 24 hours after CABG

NCT ID: NCT01915407 Completed - Clinical trials for Platelet Dysfunction Due to Aspirin Ingestion

AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction

Start date: April 2013
Phase: N/A
Study type: Observational

To test the AggreGuide A-100 AA Assay's effectiveness for detecting aspirin induced platelet dysfunction.

NCT ID: NCT01880047 Completed - Clinical trials for Immune Thrombocytopenia

Safety and Efficacy of Eltrombopag at Escalated Doses

Start date: February 2013
Phase: Phase 2
Study type: Interventional

Study rationale is based on the data that in previous clinical studies of eltrombopag in ITP there are some patients who have been reported as non responders at the maximal approved dose of 75 mg daily. The trend in both normal volunteers and in patients with ITP suggest and increasing response rate with increased doses of eltrombopag up to a dose of 75mg. Previously published data has shown no overt increase in toxicity in normal volunteers, oncology patients and aplastic anemia patients treated with escalated doses as high or higher than those proposed in this study. It therefore seems possible that in ITP patients who did not respond to a dose of 75mg daily, eltrombopag could be more effective at a higher dose. We propose a double blind randomized controlled trial in ITP patients who have been defined as non-responders at the maximum dose (75mg) of eltrombopag, assessing efficacy and toxicity at higher daily doses (100mg, 125 mg, 150 mg)

NCT ID: NCT01839968 Completed - Clinical trials for Acquired Platelet Disorder

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

Start date: September 2011
Phase: N/A
Study type: Observational

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

NCT ID: NCT01787552 Completed - Clinical trials for Hematologic Diseases

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Start date: May 8, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the combination and b) to assess the efficacy of the co-administration of LDE225 and INC424 on spleen volume reduction.

NCT ID: NCT01526460 Completed - Clinical trials for Platelet Dysfunction

Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention

STATIPLAT
Start date: August 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of a loading dose of two different statins on platelet reactivity (atorvastatin, metabolized by CYP3A4, and rosuvastatin, which is rather independent of this enzyme)in patients at least 5 days in therapy with aspirin and clopidogrel (with or without an undergoing treatment with statins) undergoing PCI for coronary disease with chronic stable angina and/or evidence of inducible myocardial ischemia.

NCT ID: NCT01454427 Completed - Clinical trials for Platelet Dysfunction

Influence of Anesthesia Drugs on Impedance Aggregometry

Start date: October 2010
Phase: N/A
Study type: Observational

Impedance aggregometry (IA) (Multiplate®)is a new whole blood platelet function test with potential use in anesthesia and intensive care. Most anesthetic drugs have been shown to have in vitro antiplatelet activity. The goal of this in vitro study is to evaluate the effect of several drugs, frequently used in cardiac anesthesia and intensive care, on platelet function as measured by IA

NCT ID: NCT01382134 Completed - Clinical trials for Platelet Dysfunction

Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction

Start date: July 2011
Phase: N/A
Study type: Interventional

Study hypothesis: Desmopressin (DDAVP) can improve platelet function under influence of aspirin, hemodilution and mild hypothermia Mild hypothermia (34-35oC) is known to cause platelet dysfunction. This could lead to increased surgical bleeding and increased transfusion requirement during surgery. Although this hypothermia-induced platelet dysfunction seems to be reversible with warming, this is not always possible or desirable. Desmopressin (DDAVP) is a drug which has proven efficacy in improving platelet function in uraemic and cirrhosis patients, and in reducing blood loss in selected surgeries. In a recent study, we have found that subcutaneous injection of 1.5 mcg (1/10th the usual dose) is already sufficient to fully reverse the platelet dysfunction seen at 32oC. We have demonstrated in another study that prolongation of the bleeding time in a 20% hemodiluted sample predicts increased postoperative bleeding after total knee replacement. We have therefore designed this study as a follow up to our last two studies on DDAVP and hypothermia, to investigate whether hemodilution affects hypothermia induced platelet dysfunction and the response to DDAVP. In addition, another common cause of perioperative platelet dysfunction is the intake of COX inhibitors, particularly aspirin by patients. Therefor the effect of aspirin on hypothermia induced platelet dysfunction and the response to DDAVP, will also be investigated.